Smith & Nephew PLC
SN.
Company Profile
Business description
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Contact
Hatters Lane
Building 5, Croxley Park
WatfordHertfordshireWD18 8YE
GBRT: +44 1923477100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
17,000
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,461.10 | 36.90 | -0.43% |
| CAC 40 | 8,051.07 | 39.92 | -0.49% |
| DAX 40 | 22,410.27 | 15.66 | -0.07% |
| Dow JONES (US) | 43,621.16 | 159.95 | 0.37% |
| FTSE 100 | 8,668.67 | 9.69 | 0.11% |
| HKSE | 23,588.33 | 554.31 | 2.41% |
| NASDAQ | 19,026.39 | 260.54 | -1.35% |
| Nikkei 225 | 37,911.64 | 326.15 | -0.85% |
| NZX 50 Index | 12,430.45 | 123.18 | 1.00% |
| S&P 500 | 5,955.25 | 28.00 | -0.47% |
| S&P/ASX 200 | 8,223.10 | 28.80 | -0.35% |
| SSE Composite Index | 3,362.11 | 16.07 | 0.48% |